Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …

Abstract ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP
inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc …

The tumour suppressor breast cancer type 1 susceptibility protein (BRCA1) promotes DNA
double-strand break (DSB) repair by homologous recombination and protects DNA …

Ovarian cancer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP
inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by …

INTRODUCTION Advances in DNA sequencing technology have enabled the widespread
analysis of breast tumor genomes, creating a catalog of genetic mutations that may initiate or …

ABSTRACT Background BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired
homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents …

Genetically engineered mouse models (GEMM s) have contributed significantly to the field of
cancer research. In contrast to cancer cell inoculation models, GEMM s develop de novo …

Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …